An update on the analysis of non-melanoma skin cancer in the tofacitinib ulcerative colitis programme

(1) Icahn School of Medicine at Mount Sinai,New York,United States

(2) University of North Carolina, Center for Gastrointestinal Biology and Disease,Chapel Hill,United States

(3) Northwestern University School of Medicine,Chicago,United States

(4) Medical University of Vienna,Vienna,Austria

(5) Hospital Clínic de Barcelona, IDIBAPS, CIBERehd,Barcelona,Spain

(6) Pfizer Inc,Collegeville,United States



This item was part of the IBD: New drugs, new risks session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019